(Pidilizumab)Biosimilar Reference Antibody-GS40547

货号：GS40547

Pidilizumab (CT-011) is a humanized IgG1-kappa monoclonal antibody that was primarily investigated in clinical trials for its potential in cancer immunotherapy and later explored in other conditions. Its development has been focused on hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL) and multiple myeloma, with studies assessing its use as a monotherapy or in combination with other treatments. Unlike many immune checkpoint inhibitors that target pathways like PD-1/PD-L1, Pidilizumab was initially described as targeting PD-1 (Programmed Death-1) but its precise mechanism of action has been the subject of some scientific discussion and may involve interactions beyond or distinct from classical PD-1 blockade.